Dipyrithione

Dipyrithione

SCHEMBL2405182

[O-][n+]1ccccc1SSc1cccc[n+]1[O-].[Zn+2]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.95
HTT P42858 2/20 0.95
SLC2A1 P11166 1/20 0.55
KDM4E B2RXH2 3/20 0.52
TDP1 Q9NUW8 1/20 0.52
KMT2A Q03164 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
RAB9A P51151 4/20 0.47
ALDH1A1 P00352 6/20 0.41
MAPT P10636 3/20 0.41
NPC1 O15118 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
GAA P10253 2/20 0.37
NFKB1 P19838 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dipyrithione SCHEMBL11186942 0.98 LMNA (0.91) LMNAHTTSLC2A1KDM4ETDP1
Dipyrithione SCHEMBL29364114 0.97 LMNA (1.00) LMNAHTTSLC2A1KDM4ETDP1
Dipyrithione SCHEMBL21165 0.97 LMNA (1.00) LMNAHTTSLC2A1KDM4ETDP1
Dipyrithione SCHEMBL11172937 0.95 LMNA (0.86) LMNAHTTSLC2A1KDM4ETDP1
Dipyrithione SCHEMBL22471518 0.95 LMNA (0.95) LMNAHTTSLC2A1KDM4ETDP1
Dipyrithione SCHEMBL10973086 0.95 LMNA (0.95) LMNAHTTSLC2A1KDM4ETDP1
Dipyrithione SCHEMBL11044641 0.95 LMNA (0.95) LMNAHTTSLC2A1KDM4ETDP1
Dipyrithione SCHEMBL6034282 0.95 LMNA (0.95) LMNAHTTSLC2A1KDM4ETDP1
Dipyrithione SCHEMBL10968452 0.95 LMNA (0.95) LMNAHTTSLC2A1KDM4ETDP1
Dipyrithione SCHEMBL11171931 0.93 LMNA (0.83) LMNAHTTSLC2A1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3079679-B1 METHOD OF TREATMENT OF ALOPECIA WITH MONOTERPENOIDS CELLMID LTD (AU) 2019-08-14 EP disclosed
US-20180360792-A1 Method of Treatment of Alopecia with Monoterpenoids Cellmid Limited (AU) 2018-12-20 US disclosed
EP-2538963-B1 METHOD OF TREATMENT OR PREVENTION OF HAIR LOSS OR FOR THE ENHANCEMENT OF HAIR GROWTH ADVANGEN INT PTY LTD (AU) 2017-05-17 EP disclosed
US-9622955-B2 Method of treatment or prevention of hair loss or for the enhancement of hair growth ADVANGEN INTERNATIONAL PTY LTD (AU) 2017-04-18 US disclosed
US-20160374979-A1 Method of Treatment of Alopecia with Monoterpenoids Cellmid Limited (AU) 2016-12-29 US disclosed
EP-3079679-A1 METHOD OF TREATMENT OF ALOPECIA WITH MONOTERPENOIDS Cellmid Limited (AU) 2016-10-19 EP disclosed
WO-2016058057-A1 IMPROVED COSMETIC AND PERSONAL CARE PRODUCTS FROM LEGUMES BLUE RIBBON ROASTING PTY LTD (AU) 2016-04-21 WO disclosed
CN-103153277-B Polymer and compositions LUBRIZOL ADVANCED MATERIALS, INC. (US) 2015-11-25 CN disclosed
WO-2015085373-A1 METHOD OF TREATMENT OF ALOPECIA WITH MONOTERPENOIDS Cellmid Limited (AU) 2015-06-18 WO disclosed
US-20150044139-A1 Method of Treatment or Prevention of Hair Loss or for the Enhancement of Hair Growth ADVANGEN INTERNATIONAL PTY LTD (AU) 2015-02-12 US disclosed
CN-103153277-A Polymers and compositions LUBRIZOL ADVANCED MAT INC 2013-06-12 CN disclosed
US-20130067604-A1 Method of Treatment or Prevention of Hair Loss or for the Enhancement of Hair Growth ADVANGEN INTERNATIONAL PTY LTD (AU) 2013-03-14 US disclosed
EP-2538963-A1 METHOD OF TREATMENT OR PREVENTION OF HAIR LOSS OR FOR THE ENHANCEMENT OF HAIR GROWTH Advangen International Pty Ltd (AU) 2013-01-02 EP disclosed
WO-2011103624-A1 METHOD OF TREATMENT OR PREVENTION OF HAIR LOSS OR FOR THE ENHANCEMENT OF HAIR GROWTH ADVANGEN INTERNATIONAL PTY LTD (AU) 2011-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160374979-A1 Method of Treatment of Alopecia with Monoterpenoids FGF1, FGF2, FGFR1 LMNA 3388/4885HTT 4216/4885SLC2A1 4762/4885
US-20180360792-A1 Method of Treatment of Alopecia with Monoterpenoids FGF1, FGF2, FGFR1 LMNA 3444/4885HTT 4301/4885SLC2A1 4763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.